64 Views no discussions Share HealthInternationalLifestylePrint Asthma pill hailed in early test by: Associated Free Press – August 8, 2016 Share Share Sharing is caring! Tweet (File photo)PARIS, France (AFP) — The first new asthma pill in nearly 20 years has led to a sharp improvement in symptoms for chronic sufferers of the disease, according to an early test of the drug.A treatment called fevipiprant eased asthma symptoms, improved lung function, reduced inflammation and repaired the lining of airways, researchers reported on Friday.“This new drug could be a game-changer for future treatment of asthma,” said Chris Brightling, a professor at the University of Leicester, central England, who led the study.Asthma is a long-term disease in which the immune system in the airways goes into overdrive, and wheezing, coughing and restricted breathing are the result.People with chronic asthma can prevent or ease the symptoms by using an inhaler or steroids, but these can have hefty side effects.Fevipiprant seeks to prevent immune cells called eosinophils from moving into the bronchial walls, where they restrict and inflame the airways.In the trial reported in the British journal The Lancet Respiratory Medicine, researchers enrolled 61 asthmatics and divided them into two groups.One group was given 225mg of the drug twice a day for 12 weeks and the other participants were given a dummy lookalike pill, called a placebo.A key goal was to monitor levels of eosinophils in sputum — a long-used biomarker of asthma.People who do have not have asthma typically have an eosinophil count of less than one percent, while those with moderate-to-severe asthma have a reading of about five percent.Those who took the drug in the experiment and had moderate-to-severe asthma saw their average count of 5.4 percent fall to 1.1 percent over 12 weeks.No adverse effects were reported.Those who took the drug also reported extensive easing of symptoms, the team said.“We already know that using treatments to target eosinophilic airway inflammation can substantially reduce asthma attacks,” Brightling said in a press release issued by the university.“This new treatment, fevipiprant, could likewise help to stop preventable asthma attacks, reduce hospital admissions and improve day-to-day symptoms.”– Test hurdles –Bigger studies are needed before the prototype drug, made by Novartis, can be approved under the three-phase process to test a novel medicine for safety and effectiveness.“More research is needed and we’re a long way off seeing a pill for asthma being made available over the pharmacy counter,” Samantha Walker, director of research at the charity Asthma UK, said through Britain’s Science Media Centre.“But it’s an exciting development and one which, in the long term, could offer a real alternative to current treatments.”Novartis, on its website, says fevipiprant is now in Phase III testing, with a hoped-for date of 2019 for filing for a licence.Around 334 million people have asthma, a figure that inflicts a major burden on economies and health systems, according to a 2014 investigation, the Global Asthma Report.Fourteen percent of the world’s children experience asthma symptoms, it said — a trend that seems to have risen sharply in poor- and middle-income countries in the past couple of decades.Lifestyle and environmental influences, such as tobacco smoke, house dust mites, types of pollen and airborne particulate pollution, are known factors in asthma.But many aspects of the disease are unclear and vulnerability varies greatly according to the individual.
FSB selects Glenn Elliott as new COO August 12, 2020 Ascot adds three-year extension to Sky Sports Racing deal August 14, 2020 Share UK racing remains hopeful for crowd pilot events August 14, 2020 StumbleUpon Related Articles Submit Share Sky Sports Racing has been revealed as the UK and Ireland’s exclusive pay TV broadcast home of French racing, on a three year deal from January 1 of next year, PMU and At The Races have announced.Furthermore, At The Races is to also become the PMU’s online video streaming provider within both regions, with a full service of over 10,000 races set to be launched. Matthew Imi, Chief Executive of At The Races, explained: “This is a very exciting new partnership for us with France Galop, Le Trot and PMU and one that has immense potential. French racing is already well supported by owners and trainers in the UK and Ireland, but we will showcase the strength and quality of French thoroughbred racing throughout the year, in a way that has never been done before by UK racing media.“Sky Sports Racing will provide consistent, live broadcast coverage of French fixtures with all relevant betting information and presentation crews regularly live on site at French racecourses. “Attheraces.com will deliver in depth and comprehensive online coverage of French racing to the largest digital audience of racing fans in the UK and Ireland. “In addition, Sport Mediastream, ATR’s wholly owned video streaming platform, will make every one of PMU’s 10,000 French thoroughbred and trotting races available live to online betting operators in the UK and Ireland for the first time.”Imi continued: “We look forward to extending our long-standing relationship with PMU and now working more closely and proactively with the teams at France Galop, Le Trot and PMU on this venture which we believe will raise the already strong profile and appeal of French racing in the UK and Ireland considerably.”“We see a great opportunity for French racing in the UK and Ireland, added Cyril Linette, CEO at PMU. “At The Races will be a strong partner for us to help deliver our high quality racing to the online betting market, and at the same time generate interest with regular broadcast coverage and promotion.”